Correct..... one should have multiple molecules, relying on DIFFERENT chemistries, in development for each target. It is glib to talk about how great your molecule is, this early in testing. Nonetheless, there's always the GOOD luck element as well, and...... well, good luck in this case could represent "first to 5 billion market".
In terms of the accomplishment..... SCIO is one of the very oldest of biotechs, having started life as California Biotechnology. They should have those multiple molecules against a single target and much, much more.
The current management team is not to blame. However, they aren't allowed glib, either.
:-)
disclosure... no position, just watching as one of biotech's perennial disappointments turns it around.... watching with admiration. |
